Restricted accessOtherFirst published online 1997-9
MADIT Does Not Provide the Basis for Developing Therapeutic Strategy for Patients With Severely Depressed Ventricular Ejection Fraction With Nonsustained Ventricular Tachycardia
Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med324:781, 1991
2.
Morganroth J.Antiarrhythmic effects of β-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmias. Am J Cardiol60:10D-14D, 1987
Moss AJ, Hall J., Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med335:1933, 1996
5.
Friedman PL, Stevenson WGUnsustained ventricular tachycardia: to treat or not to treat? N Engl J Med335: 1984, 1996
6.
TheCardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med327:227, 1992
7.
Kuck KH, Siebels J., Schneider M., Geiger M., Hamburg Cardiac Arrest Study Group. Preliminary results of a randomized trial, AICD versus drugs (abstract). Rev Eur TechBiomed12:110, 1990
8.
TheAVID Investigators. Antiarrhythmics versus implantable defibrillators (AVID): Rationale, design, and methods. Am J Cardiol75:470, 1995
9.
Connolly SJ, Gent M., Roberts RS, et al. Canadian implantable defibrillator study (CIDS): Study design and organization. Am J Cardiol72:103F, 1993
10.
Klein H., Trappe HJ, Fieguth HG, Nisam S.Prospective studies evaluating prophylactic ICD therapy for high risk patients with coronary artery disease. PACE16:564, 1993
11.
Nisam S., Thomas AS, Mower M., Hauser R.Identifying patients for prophylactic automatic implantable cardioverter defibrillator therapy: status of prospective studies. Am Heart J122:607, 1991
